drugset
drugset / Trial / NCT02211144

Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally to Healthy Human Subjects

NCT02211144 ↗

Phase 1 Completed 120 enrolled Boehringer Ingelheim
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to assess the safety and pharmacokinetics of BIRB 796 BS tablets administered as multiple daily doses at various dose levels

Timeline

Start
2002-03
Primary completion
2002-11
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject BIBR 796 BS Unknown 90 mg Oral
Subject BIBR 796 BS Unknown 120 mg Oral
Subject BIBR 796 BS Unknown 150 mg Oral
Subject BIBR 796 BS Unknown 180 mg Oral

Indications

No indication recorded.